Table 1. Baseline Characteristics of Participants.
| Characteristic | Patientsa | |
|---|---|---|
| CBCR (n = 38) | CBET (n = 37) | |
| Age, mean (SD), y | 54.5 (13.5) | 53.8 (10.7) |
| Sex | ||
| Female | 29 (76.3) | 29 (78.4) |
| Male | 9 (23.7) | 8 (21.6) |
| Marital status | ||
| Single | 3 (7.9) | 4 (10.8) |
| Married | 29 (76.3) | 27 (73.0) |
| Divorced | 4 (10.5) | 6 (16.2) |
| Widowed | 2 (5.3) | 0 |
| Highest educational level | ||
| Elementary school | 23 (60.5) | 15 (40.5) |
| High school | 12 (31.6) | 16 (43.2) |
| University graduate | 3 (7.9) | 5 (13.5) |
| Postgraduate degree | 0 | 1 (2.7) |
| Work situation | ||
| Employed | 23 (60.5) | 16 (43.2) |
| Unemployed | 7 (18.4) | 12 (32.4) |
| Retired | 8 (21.1) | 9 (24.3) |
| Type of cancer | ||
| Breast | 24 (63.1) | 26 (70.3) |
| Colorectal | 1 (2.6) | 1 (2.7) |
| Gastric | 1 (2.6) | 0 |
| Prostate | 1 (2.6) | 1 (2.7) |
| Lymphoma | 11 (28.9) | 9 (24.3) |
| Solid tumor | ||
| Any | 28 (73.7) | 27 (73.0) |
| Stage I | 12 (31.6) | 16 (43.2) |
| Stage II | 11 (28.9) | 5 (13.5) |
| Stage III | 3 (7.9) | 6 (16.2) |
| Stage IV | 2 (5.3) | 0 |
| Time elapsed between cancer diagnosis and study enrollment, median (IQR), mo | 27.0 (14.0-45.5) | 25.0 (17.5-38.5) |
| Cancer treatment | ||
| Chemotherapy | 36 (94.7) | 34 (91.9) |
| Anthracyclinesb | 33 (86.8) | 31 (83.8) |
| Cumulative dose of anthracyclines, mean (SD), mg/m2 | 265.9 (76.4) | 251.7 (44.9) |
| Thoracic radiotherapy | 24 (63.2) | 24 (64.9) |
| Radiotherapy dose, mean (SD), Gy | 46.7 (6.3) | 44.3 (7.4) |
| Surgery | 26 (68.4) | 26 (70.3) |
| Adjuvant hormonal therapy | ||
| Any | 22 (57.9) | 21 (56.8) |
| Tamoxifen | 6 (15.8) | 12 (32.4) |
| Tamoxifen plus goserelin | 3 (7.9) | 3 (8.1) |
| Exemestane plus goserelin | 1 (2.6) | 0 |
| Letrozol | 12 (31.6) | 6 (16.2) |
| Trastuzumab | 5 (13.2) | 2 (5.4) |
| Pertuzumab | 3 (7.9) | 1 (2.7) |
| Cardiovascular risk factors | ||
| Diabetes | 1 (2.6) | 2 (5.4) |
| Hypertension | 15 (39.5) | 13 (35.1) |
| Dyslipidemia | 19 (50.0) | 20 (54.0) |
| Smoking habits | 4 (10.5) | 5 (13.5) |
| Depression | 12 (31.6) | 9 (24.3) |
| Overweight | 18 (47.3) | 14 (37.8) |
| Obesity | 12 (31.6) | 10 (27.0) |
| Other comorbidities | ||
| Ischemic heart disease | 3 (7.9) | 4 (10.8) |
| Atrial fibrillation | 0 | 1 (2.7) |
| Heart failure | 4 (10.5) | 4 (10.8) |
| Valvular disease | 1 (2.6) | 0 |
| Implantable cardioverter-defibrillator | 1 (2.6) | 1 (2.7) |
| Respiratory diseasesc | 6 (15.8) | 5 (13.5) |
| Musculoskeletal diseased | 7 (18.4) | 7 (18.9) |
| Othere | 5 (13.2) | 4 (10.8) |
| Left ventricular ejection fraction, mean (SD) | 55.6 (12.4) | 55.6 (8.6) |
| Medication | ||
| Anticoagulants | 0 | 1 (2.7) |
| Antiplatelet therapy | 2 (5.3) | 3 (8.1) |
| β-Blockers | 5 (13.2) | 5 (13.5) |
| Anxiolytics | 11 (28.9) | 10 (27.0) |
| Antidepressants | 12 (31.6) | 9 (24.3) |
| Diuretics | 7 (18.4) | 7 (18.9) |
| Statins | 16 (42.1) | 14 (37.8) |
| Nitrates | 0 | 1 (2.7) |
| Fibrates | 2 (5.3) | 2 (5.4) |
| ACEI | 5 (13.2) | 6 (16.2) |
| ARA II | 4 (10.5) | 6 (16.2) |
| Sacubitril or valsartan | 2 (5.3) | 0 |
| Calcium channel blockers | 4 (10.5) | 1 (2.7) |
| Insulin | 0 | 1 (2.7) |
| Antidiabetic agentsf | 1 (2.6) | 2 (5.4) |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARA II, angiotensin II receptor antagonists; CBCR, center-based cardiac rehabilitation; CBET, community-based exercise treatment.
a
Data are presented as the number (percentage) of patients unless otherwise indicated.
b
Anthracyclines and radiotherapy were given sequentially.
c
Asthma and chronic obstructive pulmonary disease.
d
Degenerative joint disease.
e
Thyroid diseases, hepatitis, HIV infection, obstructive sleep apnea, chronic kidney disease, peripheral arterial disease, vertiginous syndrome.
f
Excluding insulin.